Research Progress of Antibody-drug Conjugates in Advanced Non-small Cell Lung Cancer / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 214-218, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-928800
ABSTRACT
Lung cancer is one of the malignant tumors with the highest morbidity and mortality in the world. Non-small cell lung cancer (NSCLC) is one of the most important pathological types of lung cancer. The prognosis of advanced NSCLC is poor and medical treatment is still the main treatment option. Antibody-drug conjugates (ADCs) are the kind of potentially new anti-tumor drugs, consisting of monoclonal antibodies conjugated to the cytotoxic payloads via the synthetic linkers. They have a broad application prospect in solid tumors such as lung cancer. This article focuses on the mechanism of action and research progress of ADCs in advanced NSCLC.
.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Immunoconjugates
/
Lung Neoplasms
/
Antibodies, Monoclonal
/
Antineoplastic Agents
Type of study:
Prognostic study
Limits:
Humans
Language:
Chinese
Journal:
Chinese Journal of Lung Cancer
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS